ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1111

Urate-Lowering Therapy Is Associated with a Reduced Risk of Arrhythmias: A Systematic Review and Meta-analysis

Palapun Waitayangkoon1, Tatchaya Kanthajan2 and Thiratest Leesutipornchai3, 1MetroWest Medical Center, Framingham, MA, 2Srinakharinwirot University, Bangkok, Thailand, 3University of Hawaii, Honolulu, HI

Meeting: ACR Convergence 2023

Keywords: Cardiovascular, Drug toxicity, meta-analysis, Uric Acid, Urate

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: (1100–1123) Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster II

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Recent studies have suggested that hyperuricemia is significantly associated with an increased prevalence of atrial and ventricular arrhythmias and urate-lowering therapy (ULT) may provide cardioprotective effects by lowering uric acid level and via drug’s direct effects. However, research on the effects of ULT and arrhythmia risk is limited. We aim to conduct a systematic review and meta-analysis exploring the relationship between ULT and incident arrhythmias.

Methods: Potentially eligible studies were identified from PubMed and Embase databases from inception to May 2023. Search terms were derived from terms related to “Arrhythmias” and “Urate-lowering therapy”. The eligible study must be cohort study that consists of one cohort of patients with ULT use and another cohort of comparators without ULT use. The study must compare the prevalence of cardiac arrhythmias in each group and report effect size with 95% confidence intervals (95% CIs). The Newcastle-Ottawa quality assessment scale was used to evaluate the quality of the included studies. We performed the meta-analysis by using a random-effects model. The heterogeneity of effect size estimates was assessed using forest plots and the Q and I2 statistics.

Results: Six studies were included in the analysis with a total of12,435 subjects (7,404 subjects in ULT group and 5,031 in non-ULT group). Our results showed that ULT users had significant reductions in the risk of arrhythmias (pooled RR 0.79, 95% CI: 0.67–0.93, p = 0.004, I2= 8.4%) compared to non-ULT users (Figure 1). Subgroup analysis showed that ULT users had a reduced risk of atrial fibrillation (pooled RR 0.76, 95% CI: 0.59–0.98, p = 0.034 with I2 =12.2%) compared to non-ULT users (Figure 2), and that allopurinol users had a reduced risk of arrhythmia (pooled RR 0.66, 95% CI: 0.46–0.95, p = 0.024 with I2= 39.6%) compared to non-allopurinol users (Figure 3).

Conclusion: Our results indicate that ULT may play a potential role in protecting arrythmias in addition to lowering uric acid level. Further investigation is needed to elucidate our results and explore the detailed mechanisms.

Supporting image 1

Figure 1. Forest plot of the meta-analysis for urate-lowering therapy and risk of arrhythmias

Supporting image 2

Figure 2. Forest plot of the meta-analysis for urate-lowering therapy and atrial fibrillation

Supporting image 3

Figure 3. Forest plot of the meta-analysis for allopurinol and arrhythmias


Disclosures: P. Waitayangkoon: None; T. Kanthajan: None; T. Leesutipornchai: None.

To cite this abstract in AMA style:

Waitayangkoon P, Kanthajan T, Leesutipornchai T. Urate-Lowering Therapy Is Associated with a Reduced Risk of Arrhythmias: A Systematic Review and Meta-analysis [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/urate-lowering-therapy-is-associated-with-a-reduced-risk-of-arrhythmias-a-systematic-review-and-meta-analysis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/urate-lowering-therapy-is-associated-with-a-reduced-risk-of-arrhythmias-a-systematic-review-and-meta-analysis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology